Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

By LabMedica International staff writers
Posted on 22 Oct 2025

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford Nanopore Technologies platforms and extend the collaboration through 2032.

Building upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025, the enhanced collaboration streamlines coordination on the development and commercialization of a broader portfolio of targeted enrichment sequencing kits for the screening and diagnosis of heritable genetic disorders.

Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

"This expanded agreement underscores our commitment to advancing genetic testing solutions that simplify workflows and deliver richer insights for laboratories worldwide," said Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By deepening our collaboration with Oxford Nanopore, we are accelerating innovation in diagnostics and creating a foundation for future portfolios."

"We're pleased to expand our collaboration with Bio-Techne to bring new genetic testing solutions to laboratories worldwide. By combining Bio-Techne's diagnostics expertise and innovations with our advanced molecular sensing platform, together we can make testing faster, simpler, and more accessible," added Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies.